Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1999 Sep;65(3):606–610. doi: 10.1086/302559

The challenges of psychopharmacogenetics.

M Catalano 1
PMCID: PMC1377966  PMID: 10441566

Full Text

The Full Text of this article is available as a PDF (140.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreassen O. A., MacEwan T., Gulbrandsen A. K., McCreadie R. G., Steen V. M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997 May;131(2):174–179. doi: 10.1007/s002130050281. [DOI] [PubMed] [Google Scholar]
  2. Armstrong M., Daly A. K., Blennerhassett R., Ferrier N., Idle J. R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry. 1997 Jan;170:23–26. doi: 10.1192/bjp.170.1.23. [DOI] [PubMed] [Google Scholar]
  3. Arranz M. J., Munro J., Owen M. J., Spurlock G., Sham P. C., Zhao J., Kirov G., Collier D. A., Kerwin R. W. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998 Jan;3(1):61–66. doi: 10.1038/sj.mp.4000348. [DOI] [PubMed] [Google Scholar]
  4. Arranz M. J., Munro J., Sham P., Kirov G., Murray R. M., Collier D. A., Kerwin R. W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998 Jul 27;32(2):93–99. doi: 10.1016/s0920-9964(98)00032-2. [DOI] [PubMed] [Google Scholar]
  5. Billett E. A., Richter M. A., King N., Heils A., Lesch K. P., Kennedy J. L. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry. 1997 Sep;2(5):403–406. doi: 10.1038/sj.mp.4000257. [DOI] [PubMed] [Google Scholar]
  6. Chen C. H., Lee Y. R., Wei F. C., Koong F. J., Hwu H. G., Hsiao K. J. Lack of allelic association between 102T/C polymorphism of serotonin receptor type 2A gene and schizophrenia in Chinese. Psychiatr Genet. 1997 Spring;7(1):35–38. doi: 10.1097/00041444-199700710-00005. [DOI] [PubMed] [Google Scholar]
  7. Deckert J., Catalano M., Syagailo Y. V., Bosi M., Okladnova O., Di Bella D., Nöthen M. M., Maffei P., Franke P., Fritze J. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet. 1999 Apr;8(4):621–624. doi: 10.1093/hmg/8.4.621. [DOI] [PubMed] [Google Scholar]
  8. Frackiewicz E. J., Sramek J. J., Herrera J. M., Kurtz N. M., Cutler N. R. Ethnicity and antipsychotic response. Ann Pharmacother. 1997 Nov;31(11):1360–1369. doi: 10.1177/106002809703101114. [DOI] [PubMed] [Google Scholar]
  9. Franchini L., Serretti A., Gasperini M., Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998 Sep-Oct;32(5):255–259. doi: 10.1016/S0022-3956(98)00004-1. [DOI] [PubMed] [Google Scholar]
  10. Heils A., Teufel A., Petri S., Stöber G., Riederer P., Bengel D., Lesch K. P. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996 Jun;66(6):2621–2624. doi: 10.1046/j.1471-4159.1996.66062621.x. [DOI] [PubMed] [Google Scholar]
  11. Hwu H. G., Hong C. J., Lee Y. L., Lee P. C., Lee S. F. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry. 1998 Sep 15;44(6):483–487. doi: 10.1016/s0006-3223(98)00134-6. [DOI] [PubMed] [Google Scholar]
  12. Kapitany T., Meszaros K., Lenzinger E., Schindler S. D., Barnas C., Fuchs K., Sieghart W., Aschauer H. N., Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res. 1998 Jul 27;32(2):101–106. doi: 10.1016/s0920-9964(98)00038-3. [DOI] [PubMed] [Google Scholar]
  13. Kawanishi C., Hanihara T., Maruyama Y., Matsumura T., Onishi H., Inoue K., Sugiyama N., Suzuki K., Yamada Y., Kosaka K. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatr Genet. 1997 Autumn;7(3):127–129. doi: 10.1097/00041444-199723000-00007. [DOI] [PubMed] [Google Scholar]
  14. Kuoppamäki M., Pälvimäki E. P., Hietala J., Syvälahti E. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology. 1995 Oct;13(2):139–150. doi: 10.1016/0893-133X(95)00049-J. [DOI] [PubMed] [Google Scholar]
  15. Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., Benjamin J., Müller C. R., Hamer D. H., Murphy D. L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov 29;274(5292):1527–1531. doi: 10.1126/science.274.5292.1527. [DOI] [PubMed] [Google Scholar]
  16. Malhotra A. K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 1996 Aug;153(8):1092–1094. doi: 10.1176/ajp.153.8.1092. [DOI] [PubMed] [Google Scholar]
  17. Masellis M., Basile V., Meltzer H. Y., Lieberman J. A., Sevy S., Macciardi F. M., Cola P., Howard A., Badri F., Nöthen M. M. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998 Aug;19(2):123–132. doi: 10.1016/S0893-133X(98)00007-4. [DOI] [PubMed] [Google Scholar]
  18. Meltzer H. Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994 Sep;55 (Suppl B):47–52. [PubMed] [Google Scholar]
  19. Mihara K., Otani K., Suzuki A., Yasui N., Nakano H., Meng X., Ohkubo T., Nagasaki T., Kaneko S., Tsuchida S. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl) 1997 Sep;133(1):95–98. doi: 10.1007/s002130050376. [DOI] [PubMed] [Google Scholar]
  20. Mihara K., Otani K., Tybring G., Dahl M. L., Bertilsson L., Kaneko S. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol. 1997 Dec;17(6):467–471. doi: 10.1097/00004714-199712000-00005. [DOI] [PubMed] [Google Scholar]
  21. Peroutka S. J. The medical utility of genomics data in neuropsychiatry: mutational genetics versus association genetics. Curr Opin Biotechnol. 1997 Dec;8(6):688–691. doi: 10.1016/s0958-1669(97)80120-6. [DOI] [PubMed] [Google Scholar]
  22. Rietschel M., Naber D., Fimmers R., Möller H. J., Propping P., Nöthen M. M. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport. 1997 May 27;8(8):1999–2003. doi: 10.1097/00001756-199705260-00040. [DOI] [PubMed] [Google Scholar]
  23. Rietschel M., Naber D., Oberländer H., Holzbach R., Fimmers R., Eggermann K., Möller H. J., Propping P., Nöthen M. M. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology. 1996 Nov;15(5):491–496. doi: 10.1016/S0893-133X(96)00090-5. [DOI] [PubMed] [Google Scholar]
  24. Shih J. C., Thompson R. F. Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet. 1999 Sep;65(3):593–598. doi: 10.1086/302562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998 Nov;3(6):508–511. doi: 10.1038/sj.mp.4000425. [DOI] [PubMed] [Google Scholar]
  26. Smith M. W., Mendoza R. P. Ethnicity and pharmacogenetics. Mt Sinai J Med. 1996 Oct-Nov;63(5-6):285–290. [PubMed] [Google Scholar]
  27. Smoller J. W., Tsuang M. T. Panic and phobic anxiety: defining phenotypes for genetic studies. Am J Psychiatry. 1998 Sep;155(9):1152–1162. doi: 10.1176/ajp.155.9.1152. [DOI] [PubMed] [Google Scholar]
  28. Sodhi M. S., Arranz M. J., Curtis D., Ball D. M., Sham P., Roberts G. W., Price J., Collier D. A., Kerwin R. W. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 1995 Dec 29;7(1):169–172. [PubMed] [Google Scholar]
  29. Varner R. V., Ruiz P., Small D. R. Black and white patients response to antidepressant treatment for major depression. Psychiatr Q. 1998 Summer;69(2):117–125. doi: 10.1023/a:1024762503100. [DOI] [PubMed] [Google Scholar]
  30. Zenner M. T., Nobile M., Henningsen R., Smeraldi E., Civelli O., Hartman D. S., Catalano M. Expression and characterization of a dopamine D4R variant associated with delusional disorder. FEBS Lett. 1998 Jan 30;422(2):146–150. doi: 10.1016/s0014-5793(97)01617-7. [DOI] [PubMed] [Google Scholar]
  31. de Leon J., Barnhill J., Rogers T., Boyle J., Chou W. H., Wedlund P. J. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry. 1998 Sep;155(9):1278–1280. doi: 10.1176/ajp.155.9.1278. [DOI] [PubMed] [Google Scholar]
  32. van Praag H. M. Over the mainstream: diagnostic requirements for biological psychiatric research. Psychiatry Res. 1997 Oct 10;72(3):201–212. doi: 10.1016/s0165-1781(97)00103-0. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES